CoChat

The abuse liability of ketamine: A scoping review of preclinical and clinical studies

Le, Tuyen T., Cordero, Isabel Pazos, Jawad, Muhammad Youshay, Swainson, Jennifer, Di Vincenzo, Joshua D., Jaberi, Saja, Phan, Lee, Lui, Leanna M.W., Ho, Roger, Rosenblat, Joshua D., McIntyre, Roger S. · 2022 · Journal of Psychiatric Research
Cited by 82

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

While ketamine has been used clinically over the past decades, it has only been recently shown to be a promising therapy for treatment-resistant depression (TRD). However, ketamine and related dissociative agents may also be misused recreationally, creating significant concerns for abuse liability when prescribed for depression. Although the abuse potential of ketamine is widely recognized, there is limited evidence on the differential abuse liability of ketamine enantiomers, (S)-ketamine and (R)-ketamine. The current scoping review aims to summarize the extant literature on the abuse liability of (R,S)-ketamine and the enantiomers. A systematic search was conducted on the Embase, Medline, and APA PsycInfo databases from 1947 to July 29, 2021. Clinical and preclinical studies that assessed the abuse potential of (R,S)-ketamine, (S)-ketamine, and (R)-ketamine were screened and assessed for eligibility by two independent reviewers. A total of 65 eligible studies were identified; 55 were preclinical studies and 10 were clinical studies. Only 4 preclinical studies evaluated the abuse liability of ketamine enantiomers. Available preclinical evidence suggests that (R,S)-ketamine and (S)-ketamine have greater risk for abuse compared to (R)-ketamine. (R)-ketamine, at the antidepressant-relevant doses in rodents, appears to be safe with minimal liability for abuse. Although the abuse potential of (R,S)-ketamine is well-established in animals, limited clinical studies indicate that single or repeated ketamine administrations in professionally controlled settings did not result in misuse, dependence, diversion and/or gateway activity in patients with TRD. However, most clinical studies were retrospective and did not systematically evaluate the abuse liability of ketamine via validated psychological scales/questionnaires. Future randomized controlled trials are warranted to ascertain the abuse liability of racemic, (S)- and (R)-ketamine in TRD population, especially among patients with comorbid substance use disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jpsychires.2022.04.035

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 82

Metadata

Authors
Le, T. T., Cordero, I. P., Jawad, M. Y., Swainson, J., Di Vincenzo, J. D., Jaberi, S., Phan, L., Lui, L. M. W., Ho, R., Rosenblat, J. D., & McIntyre, R. S.
Venue
Journal of Psychiatric Research
Publisher
Elsevier BV
Published
2022-07
Volume
151
Pages
476-496
ISSN
0022-3956 (ISSN-L)
OpenAlex
W4229447912
Cited by
82
References
30
FWCI
8.00
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The abuse liability of ketamine: A scoping review of preclinical and clinical studies. https://app.cochat.ai/papers/10.1016/j.jpsychires.2022.04.035
The paper
Le, T. T., Cordero, I. P., Jawad, M. Y., Swainson, J., Di Vincenzo, J. D., Jaberi, S., Phan, L., Lui, L. M. W., Ho, R., Rosenblat, J. D., & McIntyre, R. S. (2022). The abuse liability of ketamine: A scoping review of preclinical and clinical studies. Journal of Psychiatric Research. https://doi.org/10.1016/j.jpsychires.2022.04.035

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.